Science Highlights 2023: Genitourinary Cancer

This session highlights the most clinically relevant abstracts within the Genitourinary Cancer track of the 2023 ASTRO Annual Meeting scientific program. These noteworthy scientific abstracts share important findings and feature cutting-edge research from leaders in the field. The Discussant compares and contrasts the current data to help you digest the latest science; places the study into context; and describes how the study can be put into clinical practice, if recommended. 
Highlighted abstracts include:

  • Long Term Follow-up of NRG Oncology RTOG 0415: A Randomized Phase III Non-Inferiority Study Comparing Two Fractionation Schedules in Patients with Low-Risk Prostate Cancer  
  • Long-Term Outcomes of NRG/RTOG 0126, A Randomized Trial of High Dose (79.2Gy) vs. Standard Dose (70.2Gy) Radiation Therapy (RT) for Patients with Localized Prostate Cancer  
  • TROG 15.03 Fastrack II Trial: Focal Ablative Stereotactic Radiotherapy for Cancers of the Kidney 
  • Formula-509 Trial: Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy and 6 Months of GnRH Agonist with either Bicalutamide or Abiraterone Acetate plus Prednisone (AAP) and Apalutamide (Apa) after Radical Prostatectomy (RP)  
  • Quality of Life Outcomes in NRG/RTOG-0534

This activity is available from February 27, 2024, through 11:59 p.m. Eastern time on December 31, 2024. 

This activity was originally recorded at the 2023 ASTRO Annual Meeting in San Diego, California.

Target Audience

The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, physicists and radiation dosimetrists. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Gain knowledge of the use and technique of radiation therapy for breast cancers 
  • Assess selected randomized and comparative trials in breast cancer  
Course summary
Available credit: 
  • 0.25 Certificate of Attendance
    This activity was designated for 0.25 AMA PRA Category 1 Credit™.
Course opens: 
Course expires: 

Discussant: Leslie Ballas, MD, Cedars-Sinai Medical Center

  • Advisory Boards: Pfizer, Blue Earth Diagnostics
  • Editor: UroToday 

The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification. 

Available Credit

  • 0.25 Certificate of Attendance
    This activity was designated for 0.25 AMA PRA Category 1 Credit™.


Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the free member rate.

Nonmember: $79
Member: Free 

No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.

Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.

The course and its materials will only be available on the ASTRO website until December 31, 2024, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.